Does Ambroxol alleviate kidney ischemia-reperfusion injury in rats?

Document Type : Original Article


1 Department of Surgery, Faculty of Veterinary Medicine, Near East University, 99138, Nicosia, Cyprus

2 Department of Biochemistry, Faculty of Veterinary Medicine, Near East University, 99138, Nicosia, Cyprus

3 Department of Histology and Embryology, School of Medicine, Marmara University, 34722 Istanbul, Turkey

4 Department of Pharmacology, Faculty of Dentistry, Near East University, 99138, Nicosia, Cyprus


Objective(s): Ischemia-reperfusion injury is a life-threatening clinical problem that can occur after transplantation or a number of clinical procedures. The purpose of the study was to investigate the effects of Ambroxol on kidney damage caused by experimentally induced ischemia-reperfusion injury in rats. 
Materials and Methods: Wistar albino rats were divided into 3 groups: Control (CTR, n=6), Kidney ischemia-reperfusion (K-IR, n=6), And kidney ischemia reperfusion+Ambroxol (K-IR+AMB, n=6). In K-IR+AMB group, Ambroxol (30 mg/kg) was administered orally 30 min before the ischemia period. K-IR and K-IR+AMB groups underwent 45 min of kidney ischemia followed by a 6-hour reperfusion period. At the end of the reperfusion period, blood and kidney tissue samples were collected after euthanasia. From the blood samples, BUN and creatinine  levels were determined to assess kidney function, and TNF-α and IL-1β concentrations were evaluated to determine inflammatory response. 
Results: While serum BUN, creatinine  activities, and TNF-α and IL-1β concentrations were higher in both IR groups compared with the CTR group, these values were found to be lower in the K-IR+AMB group compared with the K-IR group. Histopathological examination revealed that interstitial edema and desquamation of tubular cells in the K-IR group were more severe than in the K-IR+AMB group. 
Conclusion: Ambroxol treatment alleviated the production of pro-inflammatory cytokines and the harmful cellular effects in the tubular cells.


1. Eraslan E, Tanyeli A, Polat E, Yetim Z. Evodiamine alleviates kidney ischemia reperfusion injury in rats: a biochemical and histopathological study. J Cell Biochem 2019; 120:17159-17166. 
2.    Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev 2009; 23: 1-10.
3.    Liu JH, Xie CJ, Li L. Effects of ambroxol on renal function in children undergoing cardiopulmonary bypass. Zhongguo Dang Dai Er Ke Za Zhi 2009; 11: 656-658.
4.    Elfouli MM, Said ME, Emam HT, Abu-raia NH, Metwally MA. Effect of ambroxol on experimentally induced acute oxidative stress in the heart, kidney, and intestine in rats. Benha Med J 2018; 35: 317-325.
5.    Altintas R, Parlakpinar H, Beytur A, Vardi N, Polat A, Sagir M, et al. Protective effect of dexpanthenol on ischemia-reperfusion-induced renal injury in rats. Kidney Blood Press Res 2012; 36: 220-230. 
6.    Erkasap S, Erkasap N, Koken T, Kahraman A, Uzuner K, Yazihan N, et al. Effect of leptin on renal ischemia-reperfusion damage in rats. J Physiol Biochem 2004; 60: 79-84.
7.    Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485.
8.    Sehirli O, Sener E, Cetinel S, Yüksel M, Gedik N, Sener G. Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol 2008; 35: 249-255.
9.    Pisoschi AM, Pop A. The role of anti-oxidants in the chemistry of oxidative stress: a review. Eur J Med Chem 2015; 97: 55-74.
10.    Kantar A, Klimek L, Cazan D, Sperl A, Sent U, Mesquita M. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip. Respir Med 2020; 15: 511-522. 
11.    Lee CS, Jang YY, Song JS, Song JH, Han ES. Ambroxol inhibits peroxynitrite‐induced damage of α1‐antiproteinase and free radical production in activated phagocytic cells. Pharmacol Toxicol 2002; 91: 140-149.
12.    Yoshida S, Yokohira M, Yamakawa K, Nakano-Narusawa Y, Kanie S, Hashimoto N, et al. Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents. J Toxicol Pathol 2018; 31: 255-265. 
13.    Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4: 1119-1129.
14.    Beeh KM, Beier J, Esperester A, Paul LD. Anti-inflammatory properties of Ambroxol. Eur J Med Res 2008; 13: 557-562.
15.    Stetinová V, Herout V, Kvetina J. In vitro and in vivo anti-oxidant activity of ambroxol. Clin Exp Med 2004; 4: 152-158. 
16.    Kabasakal L, Sehirli AO, Cetinel S, Cikler E, Gedik N, Sener G. Mesna (2-mercaptoethane sulfonate) prevents ischemia/reperfusion induced renal oxidative damage in rats. Life Sci 2004; 75: 2329-2340. 
17.    Soares RO, Losada DM, Jordani MC, Évora P, Castro-e-Silva O. Ischemia/reperfusion injury revisited: an overview of the latest pharmacological strategies. Int J Mol Sci 2019; 20: 5034-5079.
18.    Braun JP, Lefebvre HP. Kidney Function and Damage. In: Kaneko JJ, Harvey JW, Bruss ML eds. Clinical Biochemistry of Domestic Animals. 6th ed., Elsevier Academic Press, Burlington, MA, USA, 2008: 485-529.
19.    Korkmaz A, Kolankaya D. The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail 2009; 31: 36-43.
20.    Sehirli OA, Sener G, Ercan F. Protective effects of pycnogenol against ischemia reperfusion-induced oxidative renal injury in rats. Ren Fail 2009; 31: 690-697. 
21.    Güvenç M, Cellat M, Uyar A, Özkan H, Gokcek İ, İsler CT, et al. Nobiletin protects from renal ischemia-reperfusion injury in rats by suppressing inflammatory cytokines and regulating iNOS-eNOS expressions. Inflammation 2020; 43: 336-346.
22.    Wang Y, Wang FY, Pan Z, Dai YY, Xu HJ, Jin KK, et al. Effects of ambroxol combined with low-dose heparin on TNF-alpha and IL-1beta in rabbits with acute lung injury. Chin J Physiol 2011; 27: 231-235. 
23.    Lin X, Fan Y, Wang X, Chi M, Li X, Zang X, et al. Correlation between tumor necrosis factor-α and interleukin-1β in exhaled breath condensate and pulmonary function. Am J Med Sci 2017; 354: 388-394.
24.    Serteser M, Koken T, Kahraman A, Yilmaz K, Akbulut G, Dilek ON. Changes in hepatic TNF-alpha levels, anti-oxidant status, and oxidation products after renal ischemia/reperfusion injury in mice. J Surg Res 2002; 107: 234–240.
25.    Golab F, Kadkhodaee M, Zahmatkesh M, Hedayati M, Arab H, Schuster R, et al. Ischemic and non-ischemic acute kidney injury cause hepatic damage. Kidney Int 2009; 75: 783-792.
26.    Kehinde EO, Al-Awadi KA, Al-Hunayan A, Mojiminiyi OA, Memon A, Abdul-Halim H, et al. Anti-oxidant therapy is associated with a reduction in the serum levels of mediators of renal injury following lithotripsy for renal calculi. J Endourol 2008; 22: 2537-2545.
27.    Akbari G. Role of zinc supplementation on ischemia/reperfusion injury in various organs. Biol Trace Elem Res 2020; 196: 1-9. 
28.    Cienfuegos-Pecina E, Ibarra-Rivera TR, Saucedo AL, Ramírez-Martínez LA, Esquivel-Figueroa D, Domínguez-Vázquez I, et al. Effect of sodium (S)-2-hydroxyglutarate in male, and succinic acid in female wistar rats against renal ischemia-reperfusion injury, suggesting a role of the HIF-1 pathway. Peer J 2020; 8: 1-33.
29.    Zager RA, Johnson AC, Becker K. Renal cortical lactate dehydrogenase: a useful, accurate, quantitative marker of in vivo tubular injury and acute renal failure. PloS One 2013; 8: 1-12. 
30.    Peters E, Heemskerk S, Masereeuw R, Pickkers P. Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically Ill patients. Am J Kidney Dis 2014; 63: 1038–1048.  
31.    Nielsen PM, Laustsen C, Bertelsen LB, Qi H, Mikkelsen E, Kristensen MLV, et al. In situ lactate dehydrogenase activity: a novel renal cortical imaging biomarker of tubular injury? Am J Physiol Renal 2017; 312: 465-473.